SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present at the European Association for the Study of Diabetes 60^th Annual Meeting on September 9, 2024 in Madrid. SAB’s Executive Vice President and Chief Medical Officer Alexandra Kropotova, MD, MBA will present “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.”